Kornimate/medical-research-clean huggingface dataset:
evaluating technology enabled services in perinatal depression

Conditions: Depression

Summary: investigators are evaluating a technology enabled service (tes) to support the treatment of depression in the context of a collaborative care service in obstetrics clinics.

investigators are evaluating a technology enabled service (tes) to support the treatment of depression in the context of a collaborative care service in obstetrics clinics. the tes consists of digital technologies that connect patients to care managers remotely, providing tools for monitoring patient symptoms, communication, and delivery of a digital intervention. the intervention consists of a patient-facing app for assessment and self-management of depression.

Eligibility criteria:
inclusion criteria: * english speaking * 18 years or older * referred to northwestern medicine compass program for mental health care * currently pregnant or within 3 months of delivery * moderate to severe perinatal depression (defined as a phq-9 screen greater than or equal to 10) * owns a smartphone, has used smartphone in last 7 days exclusion criteria: * experienced a pregnancy loss (miscarriage, termination, or stillbirth of the index pregnancy) * severe suicidality (as defined by the presence of a plan and intent to act on that plan) * not meeting the inclusion criteria described above

Keywords: perinatal
normal prostate: oxygenation of the prostate gland in men undergoing prostate biopsy

Conditions: Prostatic Neoplasms

Summary: this study is based on previous observation that, in men with localized prostate cancer, non-cancerous prostate tissue is hypoxic, and on the known contribution of hypoxia to the progression of cancer. patients undergoing diagnostic prostate biopsy with serum prostate specific antigen (psa) less than 10ng/ml and who have given informed consent will have oxygen measurements of the prostate and peri-prostatic tissue taken with the eppendorf electrode at the time of biopsy. the oxygenation of normal prostate tissue will be compared to that of cancerous prostate tissue. in men with negative biopsies, the prostate tissue oxygen measurements will be compared with the peri-prostatic tissue oxygen measurements.


Eligibility criteria:
inclusion criteria: * men due to undergo sextant prostate biopsy * serum psa \<10 ng/ml exclusion criteria: * previous diagnosis of prostate cancer * inability to give informed consent
birth control patch study

Conditions: Contraception

Summary: 400 healthy women needed contraception will be asked to participate in this study. half will be given evra, half will be given fc patch low. they will be expected to apply the patches for 21 days of their cycle, for 7 cycles in total. the study will compare the patterns of menstrual bleeding on these two treatments, plus how effective they are at preventing pregnancy, general safety, and their acceptability to the participants.


Eligibility criteria:
inclusion criteria: * healthy women requesting contraception aged 18-35 years old * smokers must not be older than 30 at time of informed consent * history of regular cyclic menstrual periods, normal cervical smear exclusion criteria: * pregnancy or lactation * obesity (bmi\>30), hypersensitivity to any ingredients of the study drug, significant skin reaction to transdermal preparations, any diseases/conditions that can compromise the functions of the body system (resulting in altered absorption/accumulation/ metabolism/excretion of the study drug), any diseases / conditions that may worsen under hormonal treatment

Keywords: transdermal patch bleeding pregnancy
statin impact on hepatic decompensation

Conditions: Quality of Life

Summary: the study aims to evaluate the impact of statin on hepatic decompensation.

cirrhosis is the late stage of liver damage and possess two phases:. the shift from compensated to decompensated cirrhosis is characterized by the onset of complications) which are associated with substantial morbidity and negative impact on quality of life (qol)cirrhosis and its complications have a substantial economic, social, and personal impact on affected patients, as well as their families and caregivers

Eligibility criteria:
inclusion criteria: * cirrhosis adult both sex exclusion criteria: * renal insufficiency
post pancreatitis complications study (based on a prospective data base)

Conditions: Pancreatitis

Summary: the purpose of this observational epidemiological study is to investigate the management and the complications associated with pancreatitis. datas will be analysed to answer pre-defined scientific projects and to improve management of these conditions.

anonymous datas will be collected by study coordinators in a secured e-database. cross audit will be performed to check datas.

Eligibility criteria:
inclusion criteria: * pancreatitis exclusion criteria: * consent withdrawal

Keywords: pancreatitis
a trial to investigate efficacy and usability of published best practice to control glycaemia

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of the study is to compare the efficacy of enhanced published best practice paper-based insulin titration protocol for glycaemic control in hospitalised patients with type 2 diabetes for the length of hospital stay.


Eligibility criteria:
inclusion criteria: * type 2 diabetes * blood glucose in the range between 140 - 400 mg/dl * expected stay ≥ 48 hours exclusion criteria: * hyperglycemia without known history of type 2 diabetes mellitus * impaired renal function (serum creatinine ≥3.0mg/dl) * clinically relevant hepatic disease
clinical evaluation of internal fit of milled biohpp polyetheretherketone (peek) - based versus zirconia-based single crowns

Conditions: Badly Decayed Teeth andTeeth Restored With Large Filling Restorations and Endodontically Treated Teeth and Malformed Teeth and Malposed Teeth

Summary: all ceramic crowns are indicated in case of mild to moderate discoloration, restoration of traumatized or fractured teeth and abnormal tooth anatomy. the success of dental restorations is determined by four main factors: biocompatibility, aesthetic value, resistance to fracture and marginal adaptation. . an inadequate marginal fit may compromise the longevity of the restoration since cement film exposure to the oral environment can lead to its dissolution . . polyetheretherketone (peek) is a polymer that has many potentials uses in dentistry. polyetheretherketone (peek) can be used to support fixed dental prostheses. however, information about physio mechanical characterization is still scarce. aim of the study: - the aim of this study is to evaluate the internal fit of milled biohpp peek-based versus zirconia-based single crowns.


Eligibility criteria:
inclusion criteria: * from 18-50 years old, be able to read and sign the informed consent document. * patient have no active periodontal or pulpal diseases, have teeth with good restorations * patient psychologically and physically able to withstand conventional dental procedures * patients with teeth problems indicated for single posterior crowns: exclusion criteria: * patient less than 18 or more than 50 years * patient with active resistant periodontal diseases * patients with poor oral hygiene and uncooperative patients * patients in the growth stage with partially erupted teeth * patient with psychiatric problems or unrealistic expectations * patient with lack of opposing dentition in the area of interest
treatment effects of two pharmaceutical skin care creams for xerotic feet among persons with diabetes

Conditions: Diabetes Mellitus; Skin and Connective Tissue Diseases

Summary: introduction diabetic foot-ulcers leads to decreased quality of life, risk of major amputation, and resource demanding health-care. to minimize the risk of developing foot-ulcers, persons with diabetes are given the advice to daily inspect their feet and to apply skincare formulations. however, commercially available skincare products have rarely been developed and evaluated for diabetes foot care specifically. the primary aim of this randomized controlled trial (rct) is to evaluate the effects in reducing foot xerosis in persons with diabetes without foot-ulcers using two skincare creams containing different humectants (interventions) against a cream base non-humectant (comparator). secondary outcomes are to evaluate differences on skin barrier integrity, low-molecular weight biomarkers and skin microbiota, microcirculation including transcutaneous oxygen pressure, degree of neuropathy, and hba1c between intervention-comparator cream. methods two-armed double-blind rct. with 80% power, two-tailed significance of 2.5% in each arm, 39 study persons is needed in each arm, total 78 persons, to be able to prove a reduction of at least one category in the xerosis severity scale with the intervention creams compared to the comparator. in one arm, each participant will treat one foot with one of the intervention creams (oviderm® or canoderm®), while the opposite foot will be treated with the comparator cream (decubal® lipid cream®), twice a day. if needed, participants are enrolled after a wash-out period of two weeks. the participants will undergo examinations at baseline, day 14 and day 28. discussion this rct evaluate the potential effects of humectants in skin creams against foot xerosis in persons with diabetes. the outcomes of this trial could have implications on treatment recommendations of foot care and for the prevention of foot ulcer.


Eligibility criteria:
inclusion criteria: * persons above 18 years of age diagnosed with diabetes mellitus, both type i and ii, with self-experienced dry skin. * dry skin on both feet with a xerosis severity scale (xss) score between two to six. no more than one xss score in difference between the subjects' feet. * ability to understand sufficient swedish language to complete the necessary forms and understand the procedure of the study. exclusion criteria: * known sensibility to any of the ingredients in the products. * other diagnosed skin disease on the feet. * active lesions on either foot. * treatment with local medications, including topical moisturizers or keratolytic agents on the feet, within two weeks before the beginning of the study. * potential study subjects judged unable to comply with treatment schedule and study specific information. * female of childbearing potential that do not use effective medically accepted contraception.

Keywords: diabetes mellitus dry skin self care dry feet prevention
relationship between communication and gross motor function in quadriparetic cerebral palsy

Conditions: Cerebral Palsy, Spastic Quadriplegic; Communication Disorder, Childhood; Gross Motor Delay

Summary: communication problems are frequently encountered in quadriparetic cerebral palsy. additionally, motor impairments often accompany this condition. communication problems can also reduce the benefits gained from treatments, which in turn negatively affects individuals functional independence as motor impairments persist. in this study, the researchers aimed to examine the relationship between communication function, gross motor function and functional independence level.

this study is an observational study conducted with data obtained from assessment scales and does not involve any treatment. the target population of the study consists of individuals diagnosed with quadriparetic cerebral palsy (qcp). individuals with qcp aged 0-17 years were included in the study. detailed medical histories were taken from the participants, and they were evaluated using the communication function classification system (cfcs), the pediatric functional independence measure (weefim), and the gross motor function measure-88 (gmfm-88). the aim of this study is to examine the effect of communication function on gross motor function and independence.

Eligibility criteria:
inclusion criteria: * ages between 0-17, * diagnosed with quadriparetic cerebral palsy, * participants and parents willing to participate in the study voluntarily. exclusion criteria: * having different types of cerebral palsy such as dyskinetic, ataxic and mixed type, * having spastic diparetic or hemiparetic type cerebral palsy, * having any history of surgery on the musculoskeletal system, * having received botulinum toxin injections in the last 6 months
mt-r followed by autologous stem cells transplantation in newly-diagnosed primary central nervous system lymphoma

Conditions: Primary Central Nervous System Lymphoma

Summary: the purpose of this study is to evaluate the efficacy and safety of chemotherapy with mt-r followed by autologous stem cells transplantation in newly-diagnosed primary central nervous system lymphoma.

it's a single center, single arm, prospective clinical trial. patients younger than 65 years old with primary central nervous system lymphoma will received four cycles of chemotherapy with rituximab plus high-dose methotrexate and temozolomide as induction therapy, and then received consolidation therapy with autologous stem cell transplant for which the conditioning regimen is carmustine plus thiotepa.

Eligibility criteria:
inclusion criteria: * primary central nervous system diffuse large b-cell lymphoma histologically confirmed by brain biopsy * ecog 0-2 * absence of systemic disease as evaluated by chest-abdomen-pelvis ct scan * leucocytes\>3.500/mm3, platelets\>130.000/mm3, bilirubin \ 50 ml/min/1.73m2 * age 18-65 years * negative hiv test * signature of informed consent exclusion criteria: * prior chemotherapy for primary central nervous system lymphoma * presence of another cancer (excepting basal cell carcinoma of the skin and cervical carcinoma in situ ) * systemic lymphoma (outside the cns) * isolated ocular lymphoma * immunosuppressed patients (hiv , use of immunosuppressors) * other uncontrolled or progressive disease compromising shot-term survival * severe renal or hepatic disease * patients not legally covered by the french social security * inability to swallow the medication

Keywords: primary central nervous system lymphoma rituximab methotrexate and temozolomide autologous stem cell transplantation carmustine and thiotepa
comparison of 2l nrl994 with nap preparation in colon cleansing prior to colonoscopies for colon tumor screening

Conditions: Colonoscopy

Summary: to compare the efficacy, acceptability and safety of the new 2 liter gut cleansing solution (moviprep) and nap preparation in routine colon cleansing prior to tumor screening colonoscopies

this was a randomized and multicenter phase iii study in ambulatory subjects undergoing an elective colonoscopy for colon cancer screening. gut cleansing was performed using either the 2 liters of moviprep gut lavage solution or the 90 ml nap-containing preparation prior to colonoscopy. efficacy, acceptability and safety assessments was performed.

Eligibility criteria:
inclusion criteria: 1. the subject's written informed consent had to be obtained prior to inclusion. 2. male or female ambulatory subjects with an age of 18 to 85 years planned to undergo a complete colonoscopy for colon cancer screening 3. willing, able and competent to complete the entire procedure and to comply with study instructions 4. females of childbearing potential had to employ an adequate method of contraception exclusion criteria: 1. ileus 2. intestinal obstruction or perforation 3. toxic megacolon 4. history of colonic resection 5. requirement for permanent medication and associated stable serum concentrations (e.g. neuroleptic drugs) 6. congestive heart failure (nyha iii + iv) 7. acute life threatening cardiovascular disease 8. untreated or uncontrolled arterial hypertension (max. \> 170 mmhg and min \> 100 mmhg) 9. known moderate to severe renal insufficiency 10. severe renal failure 11. severe liver failure 12. known glucose 6 phosphatase dehydrogenase deficiency 13. known phenylketonuria 14. known hypersensitivity to polyethylene glycols, nap and/or vitamin c 15. concurrent participation in an investigational drug study or participation within 30 days of study entry 16. females who were pregnant, nursing or planning a pregnancy. females of child bearing potential not using reliable methods of contraception 17. subject had a condition or was in a situation, which in the investigators opinion might have put the subject at significant risk, might confound the study results, or might interfere significantly.

Keywords: colon cleansing polyethylene glycol sodium phosphate
internet-based acceptance and commitment training for elite ice hockey players

Conditions: Performance Enhancement; Performance Anxiety; Mental Health

Summary: the aim of this study is to investigate whether an internet-based psychological training program will enhance performance and affect mental health related factors in elite ice hockey players. the psychological training program is based on acceptance and commitment therapy (act), a modern form of cognitive behavior therapy, and is delivered over the internet (hence called "i-act"). elite players in sweden will be invited before the 2019/2020 season. i-act will start for enrolled participants during the first week of october 2019 (30th september- 2nd october depending on the schedule of the particular league; approximately 5 games have then been played in the leagues eligible for participation). i-act consists of seven weekly modules/chapters with act content and participants also have a psychological trainer in the program that they can contact via a chat function on the web platform. participants will have completed i-act the 17th of november 2019. when i-act starts in october, other eligible players will have the opportunity to leave their notice of interest for participation in the study and to take part of i-act in a later stage of the season. this concurrent "waiting list" is not a waiting list control group in any sense. it only gives further eligible players the opportunity to enroll in the study for a consecutive start of the psychological training program. i-act will start for this second group of players during the last week in november (25th november 2019), and finish i-act the 12th january 2020. these two consecutive groups of i-act participants will be considered the experimental group. however, due to the length of the ice hockey season the second group will only have follow-up measurements at 1 month for female players (the women's league ends in february 2020) and 2 months for male players (the men's leagues ends in march 2020). official statistics will be collected from the leagues and enrolled participants will be compared to non-participant players in the leagues to compare the effectiveness of i-act on ice hockey performance. only within-group comparisons will be made for secondary outcome measures.


Eligibility criteria:
inclusion criteria: * playing ice hockey on elite level in any of the following leagues: svenska damhockeyligan (sdhl, the swedish premier ice hockey league for women), svenska hockeyligan (shl, the swedish premier ice hockey league for men), hockeyallsvenskan (the swedish second highest league in ice hockey for men). exclusion criteria: * players currently participating in any other individual psychological training program.

Keywords: internet intervention applied sport psychology performance enhancement acceptance and commitment training elite ice hockey
a prospective patient registry of patients exposed to bedaquiline

Conditions: Pulmonary Multi-drug Resistant Tuberculosis

Summary: the purpose of this study is to describe the medical indication and utilization of expert medical consultation among participants treated with bedaquiline (bdq), bdq susceptibility based on minimum inhibitory concentrations (mics) reported for baseline and subsequent isolates, bdq drug utilization data to include dose, duration, past treatment history, past medical history, concomitant medications, and health care site of treatment, drug distribution mechanisms used in the administration of bdq, patient outcomes (clinical and microbiologic) and adverse events among bdq-treated participants, including deaths.

this is a prospective (observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group) observational (clinical study in which participants may receive diagnostic, therapeutic, or other types of interventions, but the investigator does not assign participants to specific interventions) study of participants treated with bdq. participants will be enrolled by their healthcare provider once the healthcare provider decides to treat with bdq or after bdq treatment initiation but prior to observation of any participant outcomes. all participants meeting the inclusion criteria and providing informed consent for participation in the study will be enrolled in this study. the registry enrollment period will be open for 36 months with an additional 24 months bdq treatment-free follow-up for safety assessment for the last participants enrolled during the 36 months enrollment period. participants' follow-up data will be collected at each visit from the healthcare provider during the course of bdq and for an additional 24 months after the last bdq dose or until the participant is lost to follow-up. participants' safety will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: * participants capable of providing informed consent, which must be obtained prior to collection of any patient outcomes and documented laboratory and clinical variables to meet the study objectives * participants who have documented enrollment in the bedaquiline patient registry (bpr) prior to the start of bdq treatments and documented initiation of bdq treatment after enrollment * participants who have documented initiation of bdq treatment prior to enrollment and have no documented patient outcomes and documented laboratory and clinical variables to meet the objectives of the study exclusion criteria: * no specific exclusion criteria will be applied in this study other than those scenarios that follow from the inclusion criteria

Keywords: pulmonary multi-drug resistant tuberculosis bedaquiline sirturo observational prospective
assessment of efficacy and safety of tegaserod in male patients with chronic constipation.

Conditions: Chronic Constipation

Summary: tegaserod (htf919) is an aminoguanidine indole compound and a member of a class of subgroup-selective 5-hydroxytryptamine (5-ht) agonists. the aim of this study was to evaluate the efficacy and safety of tegaserod on bowel habits in male patients with chronic constipation.


Eligibility criteria:
inclusion criteria: * a 6-month history of constipation defined as \ 1 of the following symptoms \>25% of the time: hard stools, sensation of incomplete evacuation and straining exclusion criteria: * patients with cancer, inflammatory bowel disease or other structural bowel disease * past or current diagnosis of irritable bowel syndrome were excluded. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: male patients, chronic constipation, tegaserod